

VRL/SEC/EXCHANGE

22.05.2025

<p>National Stock Exchange of India Ltd. 5th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051</p>	<p>BSE Limited 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai Script Code: 526953</p>
---	--

Sub.: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref.: Venus Remedies Secures Ukrainian GMP Renewal, Strengthening Global Pharmaceutical Presence

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith a press release being issued by the Company on the captioned subject.

Thanking you.

**Yours faithfully,
for Venus Remedies Limited**

**Neha
(Company Secretary)**

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany





PRESS RELEASE

Venus Remedies Secures Ukrainian GMP Renewal, Strengthening Global Pharmaceutical Presence

Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards

Chandigarh, May 22, 2025 – Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading global pharmaceutical company, has successfully renewed its Good Manufacturing Practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control (SMDC). The certification applies to the company's Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections.

"Renewal of the Ukrainian GMP certification underlines our unwavering commitment to maintaining world-class manufacturing standards. This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects," said Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre.

Ukraine, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S)—a consortium comprising 56 countries spanning Europe, Asia, Oceania, and the Americas—further amplifies the global acceptance and strategic importance of this certification. Venus Remedies already has a robust presence in 32 PIC/S countries, including South Africa, Thailand, Malaysia, Saudi Arabia, and Australia, with plans for continued expansion.

The Ukrainian pharmaceutical market, projected to grow at a CAGR of 3.9% and reach US\$822.26 million by 2029, is driven largely by increased demand for generics and oncology treatments. Venus Remedies, with over two decades of experience in Ukraine and 44 product registrations to date, views this certification as pivotal for sustained growth and expanded access within the broader Asia Commonwealth of Independent States (CIS) region.

Aditi K. Chaudhary, President, International Business, Venus Remedies Ltd, emphasized, "Ukraine continues to be a key strategic market for us. This renewed GMP certification enhances our credibility with regulators and partners across the region, enabling us to deepen our market presence, expand product portfolios, and provide high-quality medicines to a wider patient base."

Venus Remedies' certified Baddi Unit-II facility, equipped with advanced infrastructure and cutting-edge technologies, is strategically designed to address complex therapeutic needs and meet evolving global healthcare demands. The company's unwavering commitment to quality is reflected in its extensive global manufacturing credentials,





including Good Manufacturing Practice (GMP) approvals from leading regulatory authorities such as EU-GMP (INFARMED), PIC/S members (Malaysia and Ukraine), SAHPRA, UNICEF, TGA, INVIMA, and WHO-GMP. Complementing these are internationally recognized ISO certifications in quality management (ISO 9001), environmental management (ISO 14001), and occupational health and safety (ISO 45001), underscoring its adherence to stringent global standards across all facilities.

About Venus Remedies Ltd (venusremedies.com)

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.

Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β -lactam/ β -lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.

